When I was going through treatment for ashermans, stem cell therapy was something that existed only in research papers and overseas clinics. I remember reading about it at 2am and feeling a complicated mix of hope and exhaustion — hope that science was moving, exhaustion that it all felt so far out of reach. That was a few years ago. In 2026, the picture looks meaningfully different.
Two major studies published at the start of this year have shifted how the medical community is talking about regenerative therapies for asherman's syndrome. One was a large meta-analysis. The other was a landmark trial published in Nature. And in March, two women with severe ashermans delivered healthy babies after stem cell treatment at a hospital in India — the first documented live births from this approach at that centre.
I want to walk you through what this research actually means — in plain English, not in the language of clinical trials. Not as medical advice, but as someone who has been in this space long enough to understand both the hope and the caveats.
Standard treatment for ashermans involves hysteroscopic surgery to remove adhesions, followed by estrogen therapy to help the lining recover. For many women, this works well. But for those with moderate to severe scarring — where the basal layer of the endometrium has been significantly damaged — the lining may not recover even after the adhesions are removed. The cells responsible for regeneration are simply not there anymore.
This is where stem cells come in. The idea is that introducing stem cells — whether from bone marrow, adipose tissue (fat), umbilical cord, or the patient's own blood — can help regenerate the endometrial lining from below. Rather than just removing scar tissue, you are trying to restore the tissue-making capacity that was destroyed.
Platelet-rich plasma (PRP) is a related but distinct approach. PRP is derived from the patient's own blood, centrifuged to concentrate growth factors, and infused into the uterine cavity. It is less invasive than stem cell transplantation and has been used clinically for several years, with promising early data on lining thickness improvement and pregnancy outcomes.
The biggest piece of research published this year is a systematic review and meta-analysis in the European Journal of Obstetrics and Gynaecology (January 2026, PubMed ID 41616500). It pooled data from multiple clinical trials on mesenchymal stem cell (MSC) therapy in women with thin endometrium and asherman syndrome.
The headline findings were striking:
A 2.35mm average increase in lining thickness might not sound dramatic — but for women whose lining has been stuck at 4 or 5mm for years, that shift can be the difference between a failed transfer and a viable pregnancy. The live birth rate benefit (OR 2.27, p=0.01) is particularly significant: this is not just about getting pregnant, but about staying pregnant.
Importantly, no serious adverse events were reported across the pooled data. The largest gains came from endometrial-derived and adipose-derived MSC groups.
Published in Nature Communications in January 2026, this study tested autologous CD133+ bone marrow stem cell therapy in 20 women with moderate to severe ashermans. The treatment involved mobilising the patient's own bone marrow stem cells, harvesting them, and infusing them directly into the endometrial blood vessels.
The results showed a significant structural change in the uterine cavity: IUA (intrauterine adhesion) scores dropped from 8.0 before treatment to 4.42 after treatment — a statistically significant improvement (p<0.0001). More visibly, hysteroscopic images before and after showed a dramatically widened cavity in most patients.
At the cellular level, the researchers found a 62% increase in endometrial gland density and a 64% reduction in fibrotic stroma — essentially, the scarred, fibrous tissue was being replaced with functional tissue. This is what makes this approach different from simply removing adhesions: it is rebuilding the architecture from within.
In March 2026, Sir Ganga Ram Hospital in India published results from a clinical trial using umbilical cord-derived mesenchymal stem cells in 10 women with severe ashermans. Two of those women — who had been told their chances of natural pregnancy were effectively zero — delivered healthy babies. The others remain in follow-up.
This matters because severe ashermans is the hardest category to treat. Standard hysteroscopy often cannot restore adequate lining in these cases. These live births are not a cure, and this is a small trial. But they represent a proof of concept that regenerative approaches can work even in the most difficult presentations.
PRP (platelet-rich plasma) is a more accessible, less experimental option that has been used for several years by fertility specialists, particularly for women with a thin uterine lining who are preparing for IVF transfer. It involves drawing blood, spinning it to concentrate the growth factors, and infusing the resulting plasma into the uterine cavity.
Several case series and smaller studies have shown improvements in endometrial thickness and successful pregnancies in women whose linings had previously failed to respond to standard estrogen protocols. PRP is being investigated specifically for ashermans in ongoing research, and some clinics already offer it as an adjunct treatment after adhesiolysis.
PRP is not a replacement for hysteroscopy. But for women who have had their adhesions treated and are still struggling with a thin lining, it is a meaningful option to discuss with a reproductive endocrinologist.
For women in the United States, Yale Medicine is currently recruiting for a clinical trial specifically investigating bone marrow stem cell mobilisation for the treatment of asherman syndrome, atrophic endometrium, and recurrent implantation failure. Participants must be aged 18–40. If you are in the US and dealing with a severe or treatment-resistant case, this may be worth looking into with your specialist.
The honest answer is that stem cell therapy for ashermans is not yet a standard treatment. Most women will still be treated with hysteroscopic adhesiolysis and estrogen support — and for many, that is enough. The research I have described above represents the cutting edge of where treatment is heading, not where it currently sits in most fertility clinics.
But the direction is meaningful. The fact that we now have meta-analysis data showing a 2.7-fold improvement in pregnancy rates, live birth data from severe cases, and a major trial at one of the world's leading medical centres — this is not fringe science. This is peer-reviewed research in respected journals, and it is changing the conversations happening in specialist consulting rooms.
If you have moderate to severe ashermans that has not responded fully to standard treatment — if your periods remain very light, your lining is persistently thin, or you have had repeated failed transfers — it is worth asking your specialist specifically about PRP, about clinical trials in your region, and about what regenerative options exist.
You can read more about the standard treatment path in my article on hysteroscopy for Asherman's: what to expect, and about the link between thin lining and fertility in thin uterine lining: causes and what actually helps.
A note on unexplained infertility: Many women reading this may not yet have a formal ashermans diagnosis. If you have light periods, a history of uterine procedures, or have been given a label of unexplained infertility, the starting point is still a hysteroscopy — not regenerative therapy. Get the diagnosis first. The treatments described in this article are for women who already have a confirmed diagnosis and are not responding fully to standard care.
The Complete Guide covers the full treatment landscape — from hysteroscopy and estrogen protocols through to emerging approaches — so you can have an informed conversation with your specialist.
Get the Complete Guide — $97 Full Package — $147Stem cell therapy for ashermans is currently available through clinical trials and a small number of specialist centres, but is not yet a standard treatment offered by most fertility clinics. PRP (platelet-rich plasma) is more widely available as an adjunct treatment for thin endometrial lining following ashermans treatment. Ask your reproductive endocrinologist what is available in your region.
Research published in 2026 shows that mesenchymal stem cell therapy can significantly increase endometrial thickness — by an average of 2.35mm in a large meta-analysis — and improve pregnancy and live birth rates in women with ashermans and thin uterine lining. The treatment works by stimulating regeneration of the endometrial tissue, not just removing scar tissue. However, results vary by severity and the therapy is still being studied in large-scale trials.
Platelet-rich plasma (PRP) shows promise as an adjunct treatment for the thin uterine lining that often persists after ashermans treatment. Several case series and small trials have shown improvements in endometrial thickness and successful pregnancies in women whose linings did not respond to estrogen alone. PRP is more accessible than stem cell transplantation and is already being used in some fertility clinics.
For severe or treatment-resistant ashermans, emerging options include stem cell therapy (bone marrow-derived, adipose-derived, or umbilical cord MSCs), PRP infusion, and participation in clinical trials. Yale Medicine is currently running a trial for bone marrow stem cell mobilisation in ashermans and thin endometrium. If standard hysteroscopy has not restored your lining or periods, discuss referral to a specialist ashermans centre or reproductive endocrinologist with experience in regenerative approaches.
Medical Disclaimer: This article is written from personal experience and is for informational purposes only. It is not medical advice. Please consult a qualified healthcare professional for diagnosis and treatment. The Asherman's Compass does not provide medical diagnoses.